Reviewing MAESTRO-NASH and the implications for hepatology and health systems in implementation/accessibility of Resmetirom
Around 5.3% of adults worldwide are living with metabolic dysfunction-associated steatohepatitis (MASH). As liver fibrosis develops, their incidenc…
